Nuvectis Pharma (NASDAQ:NVCT) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Nuvectis Pharma (NASDAQ:NVCT) posted its quarterly earnings data on Tuesday. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01, RTT News reports. During the same quarter in the previous year, the business earned ($0.37) earnings per share.

Nuvectis Pharma Price Performance

NVCT traded up $0.17 during trading on Wednesday, reaching $7.60. 48,815 shares of the stock were exchanged, compared to its average volume of 102,267. Nuvectis Pharma has a 1 year low of $5.85 and a 1 year high of $12.10. The business’s 50 day moving average price is $6.79 and its two-hundred day moving average price is $6.67. The company has a market capitalization of $141.74 million, a price-to-earnings ratio of -5.86 and a beta of 0.41.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of Nuvectis Pharma in a research report on Tuesday, August 6th.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.